Novus Diagnostics is proud to announce that we have successfully raised $12 million in our latest funding round, marking a pivotal moment in our journey to revolutionize critical care diagnostics. At Novus Diagnostics, we are driven by the conviction that when a patient is critically ill, providing doctors with accurate and timely information can mean the difference between life and death. The significant capital infusion will be directed toward accelerating the development, clinical validation, and broader deployment of our groundbreaking diagnostic platform, with a special focus on our flagship product, SepTec.
SepTec is designed to confront the global sepsis crisis—a condition that tragically claims over 11 million lives annually—by offering rapid detection and precise characterization of blood stream infections within just 15 minutes. By integrating novel electrochemical sensors, centrifugal microfluidics, and automated sample processing and analysis, our technology empowers healthcare professionals to initiate life-saving, targeted therapies much earlier than traditional diagnostic methods allow.
This funding milestone not only bolsters our ability to refine and scale our innovative technologies but also strengthens our commitment to transforming the landscape of critical patient care. With this financial backing, our driven team of experts is more motivated than ever to push the boundaries of diagnostic science and make a tangible impact on global health outcomes. As we advance into this exciting phase, Novus Diagnostics reaffirms its mission to equip doctors with the right information at the right time, ultimately striving to save lives and address some of the most pressing challenges in modern medicine.
